USRE46555E1 - Deuterated catecholamine derivatives and medicaments comprising said compounds - Google Patents

Deuterated catecholamine derivatives and medicaments comprising said compounds Download PDF

Info

Publication number
USRE46555E1
USRE46555E1 US14/464,568 US200714464568A USRE46555E US RE46555 E1 USRE46555 E1 US RE46555E1 US 200714464568 A US200714464568 A US 200714464568A US RE46555 E USRE46555 E US RE46555E
Authority
US
United States
Prior art keywords
dihydroxyphenyl
amino
propionic acid
dideutero
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/464,568
Inventor
Rudolf-Giesbert Alken
Frank Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Priority to US14/464,568 priority Critical patent/USRE46555E1/en
Assigned to IMPHAR AKTIENGESELLSCHAFT reassignment IMPHAR AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: IMPHAR AKTIENGESELLSCHAFT, RATIOPHARM GMBH
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RATIOPHARM GMBH
Application granted granted Critical
Publication of USRE46555E1 publication Critical patent/USRE46555E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.

Description

The invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds.
Know representatives of catecholamines, such as L-dopa (levodopa) as well as their carboxylic acid esters, are utilized, among other things, for the treatment of Parkinson's disease and restless leg syndrome. Such a pharmaceutical which contains levodopa is, for example, Dopaflex®. L-dopa acts on the dopamine concentration in neurons of the brain. Unlike dopamine itself, it can pass through the blood-brain barrier and is converted to dopamine in the brain.
In addition, levodopa is administered in combination with active additives in pharmaceuticals. Combinations of levodopa are used with peripheral decarboxylase inhibitors, with inhibitors of the enzyme catechol-O-methyltransferase (COMT), with inhibitors of the enzyme monoamine oxidase (MAO) and with dopamine β-hydroxylase inhibitors.
In this connection, the decarboxylase inhibitors used are, for example: D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxybenzyl) hydrazide, glycine-2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine-2-(2,3,4-trihydroxybenzyl) hydrazide. Examples of combination preparations of levodopa and decarboxylase inhibitors include, among others: Madopar® (levodopa and benserazide hydrochloride) as well as Nacom® (levodopa and carbidopa).
Examples of COMT inhibitors are entacapone (Comtan®) and cabergoline and frequently used MAO inhibitors are selegiline hydrochloride, moclobemide and tranylcypromine.
Calcium 5-butyl picolinate and calcium 5-pentyl picolinate are described as inhibitors for dopamine-β-hydroxylase (DE 2,049,115).
WO-A 2004/056724 discloses deuterated catecholamine having two deuterium atoms in the β-position. These compounds exhibit improved pharmacokinetic and/or pharmacodynamic properties with respect to undeuterated compounds and as compared to L-DOPA.
An object of the present invention is to prepare deuterated catecholamine derivatives, which have improved pharmacokinetic and/or pharmacodynamic properties when compared to compounds already known, as well as to prepare catecholamine derivatives, which can be utilized for the prophylaxis of psychoses including schizophrenia, and which can be used for producing pharmaceuticals for the prophylaxis of psychoses.
It has been surprisingly found that the deuterated catecholamine derivatives according to the invention have substantially better pharmacokinetic and/or pharmacodynamic properties than the undeuterated compounds and the β,β-di-deuterated compounds known in the art and that they can also be utilized for the prophylaxis of psychoses and can be used for producing pharmaceuticals for the prophylaxis of psychoses.
According to the invention, the object is thus solved by the preparation of compounds of general formula I:
Figure USRE046555-20170919-C00001
wherein
  • R1 is H or D, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
  • R2 indicates H or D,
  • R3 is H, D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
  • R4 indicates H or D, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
  • R5 is H or D, and
  • R6 is H or D,
    as well as their physiologically acceptable salts and their stereoisomers, enantiomeres or diastereomers in optically pure form.
Preferred are compounds according to general formula I wherein both residues R6 are not simultaneously Deuterium (D).
Groups that are easily hydrolytically or enzymatically cleavable under physiological conditions are known to one skilled in the art. The groups are common protective groups which are used in synthesis or that are such protective groups which lead to so-called prodrugs.
These groups may be selected from the group comprising methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1 to C6-alkyl, that may be branched or unbranched, or C5 to C6cycloalkyl, deuterated or partly deuterated C1 to C6alkyl, that may be branched or unbranched, or deuterated or partly deuterated C5 to C6-cycloalkyl.
According to the invention deuterated catecholamine derivatives according to formula 1 are preferred, wherein
  • R1 is H or D,
  • R2 indicates H or D,
  • R3 is H, D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
  • R4 indicates H or D,
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
  • R4 indicates H or D
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are also deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is H, D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
  • R4 indicates H or D,
  • R5 is D and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to the general formula I, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is C1 to C6-alkyl or C5 to C6-cycloalkyl,
  • R4 indicates H or D,
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is methyl,
  • R4 indicates H or D,
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is ethyl,
  • R4 indicates H or D
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates D,
  • R3 is perdeuteroethyl,
  • R4 indicates H or D
  • R5 is D and,
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates H or D,
  • R3 is perdeuteroethyl,
  • R4 indicates H or D,
  • R5 is D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, wherein
  • R1 is H or D,
  • R2 indicates H or D,
  • R3 is perdeuteroethyl,
  • R4 indicates D
  • R5 is H or D, and
  • R6 is H or D, under the proviso that both residues R6 are not simultaneously D.
Preferred are deuterated catecholamine derivatives according to formula 1, namely
  • 2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • 2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • 2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • D-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • D-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • D-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • D,L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • D,L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • D,L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid,
  • S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester,
  • S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid ethyl ester,
  • 2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • 2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • 2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • D-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • D-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • D-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • D,L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • D,L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • D,L-2-amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • 2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • 2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • 2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
  • S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester,
  • S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid,
  • S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester, and
  • S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid ethyl ester.
Another embodiment of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine trans-port or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for the stimulation of the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
Preferred is the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, in combination with an enzyme inhibitor or several enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
It is advantageous if the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
It is particularly advantageous if the decarboxylase inhibitor is selected from the group consisting of the following: D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
In particular, it is also advantageous if the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
It is also preferred if the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine, as well as physiologically acceptable salts thereof.
In addition, it is particularly preferred if the hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
Another subject of the invention is the use of the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the production of pharmaceuticals for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy.
Another subject of the present invention is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as their physiologically acceptable salts for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, such as Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, in addition to pharmaceutically acceptable adjuvants and additives.
Particularly advantageous is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the treatment of Parkinson's disease, restless leg syndrome, dystonia, for the inhibition of prolactin secretion, for stimulating of the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, as well as one or more enzyme inhibitors, in addition to pharmaceutically acceptable adjuvants and additives.
A pharmaceutical composition is particularly preferred in which the enzyme inhibitor or the enzyme inhibitors involve decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
Additionally preferred is a pharmaceutical composition in which the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
Particularly advantageous is a pharmaceutical composition in which the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as their physiologically acceptable salts.
Additionally advantageous is a pharmaceutical composition in which the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
In addition, a pharmaceutical composition is preferred in which the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
Another subject of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for use in the prophylaxis of psychoses, particularly in predisposed patients, for the prophylaxis of a relapse and also particularly for the treatment of acute psychoses, for example, with negative symptomatology.
Particularly preferred is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof, in combination with one or more enzyme inhibitors, for use in the prophylaxis of psychoses and for use in acute psychoses, preferably psychoses with negative symptomatology.
Particularly preferred is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof, if the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
Particularly preferred is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof, if the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
The use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof is advantageous, if the catechol-O-methyl-transferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
In addition, the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof is advantageous, if the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
The use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof is particularly advantageous, if the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
Another subject of the invention is the use of the deuterated catecholamine derivatives according to the invention as well as physiologically acceptable salts thereof for the production of pharmaceuticals for use in the prophylaxis of psychoses.
Still another subject of the invention is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for use in the prophylaxis of psychoses and for the treatment of acute psychoses, in addition to pharmaceutically acceptable adjuvants and additives.
Particularly advantageous is a pharmaceutical composition which contains the deuterated catecholamines according to the invention as well as physiologically acceptable salts thereof for the prophylaxis of psychoses and for the therapy of acute psychoses as well as one or more enzyme inhibitors, in addition to pharmaceutically acceptable adjuvants and additives.
Particularly preferred is a pharmaceutical composition in which the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and/or catechol-O-methyltransferase inhibitors and/or monoamine oxidase inhibitors and/or β-hydroxylase inhibitors.
Additionally advantageous is a pharmaceutical composition in which the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as physiologically acceptable salts thereof.
Particularly advantageous is a pharmaceutical composition in which the catechol-O-methyltransferase inhibitor is selected from entacapone and cabergoline as well as physiologically acceptable salts thereof.
Particularly advantageous is a pharmaceutical composition in which the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine as well as physiologically acceptable salts thereof.
Particularly preferred is a pharmaceutical composition in which the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate as well as physiologically acceptable salts thereof.
The production of the compounds according to the invention is known to one skilled in the art. Analogous production methods are used as described, for example, in DE-A 102 61 807.
For the production of the physiologically acceptable salts of the deuterated catecholamine derivatives according to the invention, the usual physiologically acceptable inorganic and organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid can be used. Additional acids that can be used are described, for example, in Fortschritte der Arzneimittelforschung, Vol. 10, pp. 224-225, Birkhäuser Publishers, Basel and Stuttgart, 1966, and Journal of Pharmaceutical Sciences, Vol. 66, pp. 1-5 (1977).
The acid addition salts are usually obtained in a way known in and of itself by mixing the free base or solutions thereof with the corresponding acid or solutions thereof in an organic solvent, for example, a lower alcohol, such as methanol, ethanol, n-propanol or isopropanol or a lower ketone such as acetone, methyl ethyl ketone or methyl isobutyl ketone or an ether such as diethyl ether, tetrahydrofuran or dioxane. For better crystal precipitation, mixtures of the named solvents can also be used. In addition, physiologically acceptable aqueous solutions of acid addition salts of the compounds used according to the invention can be produced there from in an aqueous acid solution.
The acid addition salts of the compounds according to the invention can be converted to the free base in a way known in and of itself, e.g., with alkalis or ion exchangers. Additional salts can be obtained from the free base by reaction with inorganic or organic acids, particularly those which are suitable for the formation of salts that can be employed therapeutically. These or also other salts of the new compound, such as, e.g., the picrate, may also serve for purification of the free base by converting the free base into a salt, separating this salt, and again releasing the base from the salt.
The subject of the present invention is also pharmaceuticals for oral, buccal, sublingual, nasal, rectal, subcutaneous, intravenous or intramuscular application as well as for inhalation, which, in addition to the usual vehicle and dilution agents, also contain a compound of general formula I or the acid addition salt thereof as an active ingredient.
The pharmaceuticals of the invention are produced, in the known way and with suitable dosage, with the usual solid or liquid vehicle substances or dilution agents and the usually used pharmaceutical-technical adjuvants corresponding to the desired type of application. The preferred preparations consist of a form of administration which is suitable for oral application. Such forms of administration include, for example, tablets, sucking tablets, film tablets, dragees, capsules, pills, powders, solutions, aerosols or suspensions or slow-release forms.
Of course, parenteral preparations such as injection solutions are also considered. In addition, suppositories, for example, have also been named as preparations. Corresponding tablets can be obtained, for example, by mixing the active substance with known adjuvants, for example, inert dilution agents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, bursting agents such as corn starch or alginic acid, binders such as starches or gelantins, lubricants such as magnesium stearate or talc and/or agents for achieving a slow-release effect such as carboxypolymethylene, carboxymethylcellulose, cellulose acetate phthalate or polyvinyl acetate. The tablets may also consist of several layers.
Dragees can also be produced correspondingly, for controlled or delayed release forms of preparation, by coating the cores produced analogously to the tablets with agents commonly used in dragee coatings, for example, polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar. The dragee envelope may also consist of several layers, wherein the adjuvants mentioned above in the case of tablets can be used.
Solutions or suspensions containing the active substance used according to the invention may additionally contain agents that improve taste, such as saccharin, cyclamate or sugar, as well as, e.g., taste enhancers such as vanilla or orange extract. They may also contain suspension adjuvants such as sodium carboxymethylcellulose or preservatives such as p-hydroxybenzoate. Capsules containing active substances can be produced, for example, by mixing the active substance with an inert vehicle such as lactose or sorbitol and encapsulating this mixture in gelatin capsules. Suitable suppositories can be produced, for example, by mixing with vehicle agents provided therefore, such as neutral fats or polyethylene glycol or derivatives thereof.
The production of the pharmaceutical preparations according to the invention is known in and of itself, and is described in handbooks known to the person skilled in the art, for example, Hager's Handbuch [Handbook] (5th ed.) 2, 622-1045; List et al., Arzneiformenlehre [Instructions for Drug Forms], Stuttgart: Wiss. Verlagsges. 1985; Sucker et al., Pharmazeutische Technologie [Pharmaceutical Technology], Stuttgart: Thieme 1991; Ullmann's Enzyklopädie [Encyclopedia] (5th ed.) A 19, 241-271; Voigt, Pharmazeutische Technologie [Pharmaceutical Technology], Berlin: Ullstein Mosby 1995.
As known from WO-A 2004/056724, L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid is a selectively deuterated L-DOPA derivative with better pharmacokinetic and pharmacodynamic properties when compared to L-DOPA. Administration of L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid to male Wistar rats increased dopamine in the striatum significantly more compared to non-deuterated L-DOPA.
It has been surprisingly found that L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid increased dopamine in the striatum significantly more than L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid, although the compound has less deuterium at the beta position of the side chain of its molecule (Example 15 and Table 1).
Furthermore, whereas L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid reduces the striatal output of norepinephrine compared to L-DOPA, L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid does not block the formation of norepinephrine.
Therefore, L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid has two advantages, it provides more dopamine and enough norepinephrine which has been shown to play an important role in compensating for the loss in dopaminergic function (Archer and Fredriksson, 2006, Neural Transm., 113(9): 1119-29; Cathala et al. 2002, Neuroscience, 115(4): 1059-65; Tong et al. 2006, Arch Neurol, 63(12): 1724-8).
The highly soluble L-DOPA methyl ester has been shown to function as a prodrug of L-DOPA. In animal experiments, L-DOPA methyl ester given orally or intraperitoneally was equivalent on a molar basis to L-DOPA. However, therapeutic equivalence was not maintained with continuous intravenous infusion in Patients with Parkinson's disease exhibiting severe on-off phenomena. The optimal infusion rate for L-DOPA methyl ester was 2.7 times that required for L-DOPA (Stocchi et al. 1992, Movement Disorders, 7: 249-256). Surprisingly, L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid methyl ester is therapeutically equivalent to L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid during continuous intravenous infusion.
The following examples are given to explain the present invention in more detail but shall not be understood to limit the scope of the invention.
EXAMPLE 1 D,L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid
2.5 g Levodopa are dissolved in 60 mL CH3CO2D under argon and then reacted with 0.25 mL benzaldehyde under reflux. Following elimination of acetic acid and benzaldehyde by distillation in vacuum, 2 mL of methanol are added. The product is precipitated slowly with 10 mL ethyl acetate/toluene (1:1). After drying under vacuum, 2.2 g D,L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid are isolated.
Yield: 87.6%
EXAMPLE 2 D,L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) methyl propionate
2.0 g of D,L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid are dissolved in 30 mL methanol and cooled to −10° C. and reacted dropwise with 1 ml of thionyl chloride. The reaction batch is then heated to 40° C. for 15-hours. The volatile substances in the reaction batch are eliminated in vacuum and 10 ml of water and 15 ml of a solution of 0.8 g of sodium hydrogen carbonate, 1 g of sodium sulfate and 1 mg of ascorbic acid are added. The pH of the solution is adjusted to a value of 7 by addition of a dilute sodium hydroxide solution. The product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol. The organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue and after this material is left to stand overnight, the D,L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate precipitates. After recrystallization from an oxygen-free methanol/diethyl ether mixture, which is combined with 2,6-di-tert-butyl-4-methoxyphenol, 1.8 g of product is isolated.
Yield: 84.9%
EXAMPLE 3 L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid
1.15 g of D,L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate are dissolved in 30 mL of a 0.2-molar sodium bicarbonate solution (pH 8.2). 200 μL of alcalase are added and the pH of the solution is kept at this value by means of carbonate-bicarbonate buffer. The course of the reaction is monitored by HPLC and the reaction is terminated by the addition of hydrochloric acid when the concentration of the propionate ester has been reduced to one-half. The deuterated amino acid contained in the solution is separated from the deuterated methyl ester chromatographically by use of the solvent system of acetonitrile/0.1% aqueous trifluoroacetic acid (15:85) and 0.51 g of L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid is isolated.
Yield: 95% (based on the proportion of L-enantiomer)
Melting point: 287-290° C.
C9H10NO4D:
calc. C, 54.54%; H, 5.09%; N, 7.07%; O, 32.29%; D, 1.02%.
found C, 54.45%; H+D, 6.08; N, 7.02.
1H-NMR (400 MHz, d6-DMSO): 6.58 (d, 1H); 6.54 (s, 1H); 6.47 (d, 1H); 3.07 (d, 1H); 2.90 (d, 1H)
EXAMPLE 4 L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate
2.0 g of L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid are dissolved in 30 mL methanol are cooled to −10° C. and reacted dropwise with 1 ml of thionyl chloride. The reaction batch is then heated to 40° C. for 15 hours. The volatile substances in the reaction batch are eliminated in vacuum and 10 ml of water and 15 ml of a solution of 0.8 g of sodium hydrogen carbonate, 1 g of sodium sulfate and 1 mg of ascorbic acid are added. The pH of the solution is adjusted to a value of 7 by addition of a dilute sodium hydroxide solution. The product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol. The organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue and after the material is left to stand overnight, the L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)methyl propionate precipitates. After recrystallization from an oxygen-free methanol/diethyl ether mixture, which is combined with 2,6-di-tert-butyl-4-methoxyphenol, 1.9 g of product is isolated.
Yield: 89.6%
C10H12NO4D:
calc. C, 56.60%; H, 5.70%; N, 6.60%: O, 30.16%; D, 0.95%.
found C, 56.65%; H+D, 6.63%; N, 6.54%.
1H-NMR (400 MHz, d6-DMSO): 6.58 (d, 1H); 6.54 (s, 1H); 6.47 (d, 1H); 3.81 (s, 3H); 3.07 (d, 1H); 2.90 (d, 1H)
EXAMPLE 5 L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl)ethyl propionate
2.0 g of L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid are dissolved in 30 mL ethanol are cooled to −10° C. and reacted dropwise with 1 ml of thionyl chloride. The reaction batch is then heated to 40° C. for 15 hours. The volatile substances in the reaction batch are eliminated in vacuum and 10 ml of water and 15 ml of a solution of 0.8 g of sodium hydrogen carbonate, 1 g of sodium sulfate and 1 mg of ascorbic acid are added. The pH of the solution is adjusted to a value of 7 by addition of a dilute sodium hydroxide solution. The product is transferred to the organic phase by extraction with oxygen-free ethyl acetate, which contains 0.01% 2,6-ditert-butyl-4-methoxyphenol. The organic phase is dried and then the solvent is distilled off 50 ml of oxygen-free diethyl ether are added to the residue, and after the material is left to stand overnight, the L-2-amino-2-deutero-3-(3,4-dihydroxyphenyl)ethyl propionate precipitates. After recrystallization from an oxygen-free ethanol/diethyl ether mixture, which is combined with 2,6-ditert-butyl-4-methoxyphenol, 2 g of product is isolated.
Yield: 88.5%
C11H14NO4D:
calc. C, 58.40%; H, 6.24%; N, 6.19%; O, 28.29%; D, 0.89%.
found C, 58.32%; H+D, 7.03%; N, 6.12%.
1H-NMR (400 MHz, d6-DMSO): 6.58 (d, 1H); 6.54 (s, 1H); 6.47 (d, 1H); 4.15 (q, 2H); 3.07 (d, 1H); 2.90 (d, 1H); 1.21 (t, 3H)
EXAMPLE 6 L-2-Amino-2,3(S)-dideutero-3-(3,4-dihydroxyphenyl) propionic acid
2.5 g of N-acetyl-3-methoxy-4-acetoxy cinnamic acid are dissolved in 30 mL methanol containing 0.027 g sodium hydroxide and placed into an autoclave. The oxygen is replaced by nitrogen before the reactor is filled with deuterium gas. At the same time 0.5 g of Monsanto catalyst are prepared in 2.5 mL toluene by treating with deuterium gas. After addition of the catalyst to the autoclave, the “hydrogenation” is started at 60° C. and 4-5 bar. After 4 hours, the excess of deuterium gas is removed and the solvent is distilled of. The sodium salt of the deuterated product is isolated and recrystallized.
Yield: 2.4 g (94%)
0.9 g of the sodium salt are dissolved in 2.5 mL of hydrobromic acid (23%) and heated to reflux at about 105-110° C. Afterwards, the reaction mixture is cooled to 25-30° C. and the pH is adjusted to 3 by addition of concentrated sodium hydroxide solution to start the precipitation of L-2-Amino-2,3(S)-dideutero-3-(3,4-dihydroxyphenyl) propionic acid. The precipitate is washed with cold water and recrystallized in hot water under protective gas. After recrystallization, 0.51 g of the product are isolated.
Yield: 85.1%
Melting point: 286-299° C.
C9H9NO4D2:
calc. C, 54.27%; H, 4.55%; N, 7.03%; O, 32.13%; D, 2.02%.
found C, 54.15%; H+D, 6.50%; N, 7.08%.
1H-NMR (400 MHz, d6-DMSO): 6.59 (d, 1H); 6.54 (s, 1H); 6.48 (d, 1H); 2.74 (m, 1H)
EXAMPLE 7
L-2-Amino-2,3(S)-dideutero-3-(3,4-dihydroxyphenyl)methyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 4).
Yield: 91%
C10H11D2NO4:
calc. C, 56.33%; H, 5.20%; N, 6.57%; O, 30.01%; D, 1.89%.
found C, 56.22%; H+D, 7.01; N, 6.45.
1H-NMR. (400 MHz, d6.-DMSO): 6.59 (d, 1H); 6.54 (S, 1H); 6.48 (d, 1H); 2.72 (m, 1H); 3.81 (s, 3H).
EXAMPLE 8 L-2-Amino-2,3(S)-dideutero-3-(3,4-dihydroxyphenyl)ethyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 5).
Yield: 93%,
C11H13D2NO4:
calc. C, 58.14%; H, 5.77%; N, 6.16%; O, 28.16%; D, 1.77%.
found C, 58.10%; H+D, 7.48%; N, 6.10%.
1H-NMR (400 MHz, d6-DMSO): 6.59 (d, 1H); 6.54 (s, 1H); 6.48 (d, 1H); 2.72 (m, 1H); 4.17 (q, 2H); 1.22 (t, 3H).
EXAMPLE 9 L-2-Amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid
0.2 g of L-2-Amino-2-deutero-3-(3,4 dihydroxyphenyl) propionic acid are placed into an autoclave and 10 mL of D2O are added. The autoclave is evacuated and heated to 190° C. for 24 hours. The solvent is eliminated and acetic acid ethyl ester is added. The solvent is distilled of and the residue washed with cold acetone. Thereafter, 0.17 g of the product are isolated.
Yield: 84%
C9H7NO4D4:
calc. C, 53.72%; H, 3.51%: N, 6.96%; O, 31.81%; D, 4.00%.
found C, 53.65%; H+D, 7.45%; N, 6.90%.
1H-NMR (400 MHz, d6-DMSO): 3.06 (d, 1H); 2.88 (d, 1H)
EXAMPLE 10 L-2-Amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 4).
Yield: 89%.
C10H9NO4D4:
calc. C, 55.80%; H, 4.21%; N, 6.51%; O, 29.73%; D, 3.74%.
found C, 55.71%; H+D, 7.89%; N, 6.53%.
1H-NMR (400 MHz, d6-DMSO): 3.81 (s, 3H); 3.08 (d, 1H); 2.88 (d, 1H)
EXAMPLE 11 L-2-Amino-2-deutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 5).
Yield: 92%.
C11H11NO4D4:
calc. C, 57.63%; H, 4.84%; N, 6.11%; O, 27.91%; D, 3.51%.
found C, 57.57%; H+D, 8.31%; N, 6.15%.
1H-NMR (400 MHz, d6-DMSO): 4.17 (q, 2H); 3.06 (d, 1H); 2.88 (d, 1H); 1.21 (t, 3H)
EXAMPLE 12 L-2-Amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid
0.2 g of L-2-Amino-2-deutero-3-(3,4-dihydroxyphenyl) propionic acid are placed into an autoclave and 10 mL of D2O are added. The autoclave is evacuated and heated to 190° C. for 24 hours. The solvent is eliminated and acetic acid ethyl ester is added. The solvent is distilled of and the residue washed with cold acetone. Thereafter, 0.16 g of the product are isolated.
Yield: 79.2%
C9H6NO4D5:
calc. C, 53.46%; H, 2.99%; N, 6.93%; O, 31.65%; D, 4.98%.
found C, 53.49%; H+D, 7.92%; N, 6.88%.
1H-NMR (400 MHz, d6-DMSO): 2.76 (m, 1H)
EXAMPLE 13 L-2-Amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)methyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 4).
Yield: 90%
C11H8D5NO4:
calc. C, 55.54%; H, 3.73%; N, 6.48%; O, 29.59%; D, 4.66%.
found C, 55.50%; H+D, 8.31; N, 6.45%.
1H-NMR (400 MHz, d6-DMSO): 3.80 (s, 3H); 2.74 (m, 1H)
EXAMPLE 14 L-2-Amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl)ethyl propionate
The compound is produced according to the description for the mono-deuterated compound (cf. example 5).
Yield: 93%
C11H10D5NO4:
calc. C, 57.38%; H, 4.38%; N, 6.08%; O, 27.79%; D, 4.37%.
found C, 57.34%; H+D, 8.71%; N, 6.04%.
1H-NMR (400 MHz, d6-DMSO): 4.15 (q, 2H); 2.75 (m, 1H); 1.21 (t, 3H)
EXAMPLE 15 Striatal Dopamine Output Measured by Microdialysis
The striatal output of dopamine was measured in Male Wistar rats following intraperitoneal administration of 50 mg/kg L-2-Amino-3-(3,4-dihydroxyphenyl) propionic acid (L-DOPA), L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid (WO-A 2004/056724, Example 6) and L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid (Example 6), respectively. Male wistar rats (BK Universal, Sollentuna, Sweden) weighing about 300 g at the time of experiment were anaesthetized with a cocktail containing fentanyl citrate (0.39 mg/kg) and fluanisone (12.5 mg/kg, Hypnorm®, Janssen-Cilag) and midazolam (6.25 mg/kg, Dormicum®, Roche) diluted in distilled water (1:1:2; 5 ml/kg i.p.) and mounted in a stereotaxic frame. Dialysis probes were implanted in the dorsolateral striatum (AP: +0.6: ML+3.0: DV −6.2 relative to bregma and the dural surface according to the atlas of Paxinos and Watson (1998)). Dialysis occurs through a semipermeable membrane (Filtral AN69, Hospal Industrie, France) with an active surface length of 3.5 mm. Dialysis experiments were conducted approximately 48 h after surgery in freely moving rats. The rats received 30 min before administration of test items 10 mg/kg Carbidopa, (i.p.). The dialysis probe was perfused with a physiological perfusion solution (Apoteksbolaget, Sweden) at a rate of 2.5 ml/min set by a microinfusion pump (Harvard Apparatus, Holliston, Mass.). Dialysate was collected over 15 min intervals and automatically injected into a high performance liquid chromatography (HPLC) system. On-line quantification of dopamine in the dialysate was accomplished by electrochemical detection (ESA, Chelmsford, Mass.). The location of microdialysis probes was verified in slices of formalin-fixed tissue stained with neutral red. The baseline corrected concentrations (fmol/min) were plotted over the time.
Comparison of AUC0-t (area under the curve) values revealed that the increase of dopamine in the striatum following administration of 50 mg/kg L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) propionic acid was about twice as high compared to L-2-Amino-3-(3,4-dihydroxyphenyl) propionic acid (L-DOPA) as displayed in Table 1. The increase of striatal dopamine following administration of 50 mg/kgL-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) propionic acid (Example 6) was even threefold higher than that measured after administration of L-DOPA.
TABLE 1
Baseline corrected dopamine output in the striatum
AUC0-t
Compound [fmol/min * min]
L-2-Amino-3-(3,4-dihydroxyphenyl) propionic acid 228
L-2-Amino-2,3,3-trideutero-3-(3,4-dihydroxyphenyl) 533
propionic acid
L-2-Amino-2,3-dideutero-3-(3,4-dihydroxyphenyl) 685
propionic acid (Ex. 6)

Claims (25)

The invention claimed is:
1. Deuterated catecholamine derivatives of the general formula I
Figure USRE046555-20170919-C00002
R1 is H or D, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
R2 indicates D,
R3 is H, D, C1 to C6 alkyl or C1 to C6-cycloalkyl, deuterated to C1 to C6 wherein alkyl or C1 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
R4 indicates H or D, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions,
R5 is H or D, and
one of R6 is H and the other R6 is D,
as well as their physiologically acceptable salts and their stereoisomers, enantiomeres or diastereomers in optically pure form.
2. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is H, D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
R4 indicates H or D, and
R5 is D.
3. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
R4 indicates H or D, and
R5 is D.
4. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is H, D, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or deuterated C5 to C6-cycloalkyl,
R4 indicates H or D, and
R5 is D.
5. Deuterated catecholamine derivatives according to the general formula I, wherein
R1 is H or D,
R3 is C1 to C6-alkyl or C5 to C6-cycloalkyl,
R4 indicates H or D, and
R5 is D.
6. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is methyl,
R4 indicates H or D, and
R5 is D.
7. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is ethyl,
R4 indicates H or D, and
R5 is D.
8. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is perdeuteroethyl,
R4 indicates H or D, and
R5 is D.
9. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is perdeuteroethyl,
R4 indicates H or D, and
R5 is D.
10. Deuterated catecholamine derivatives according to claim 1, wherein
R1 is H or D,
R3 is perdeuteroethyl,
R4 indicates D, and
R5 is H or D.
11. Deuterated catecholamine derivatives according to claim 1, namely
R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid,
R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid methyl ester,
R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester,
R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid,
R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid methyl ester,
R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester,
S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid,
S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid methyl ester,
S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester,
S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid,
S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid methyl ester,
S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid ethyl ester,
2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid,
2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid methyl ester,
2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid ethyl ester,
R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid,
R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid methyl ester,
R/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid ethyl ester,
R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid,
R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5-dihydroxyphenyl) propionic acid methyl ester,
R/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid ethyl ester,
S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid,
S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid methyl ester,
S/R-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid ethyl ester,
S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid,
S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid methyl ester, and
S/S-2-amino-2,3-dideutero-3-(2,3,6-trideutero-4,5- dihydroxyphenyl) propionic acid ethyl ester.
12. A pharmaceutical composition, which contains comprising a deuterated catecholamines according to claim 1 as well as catecholamine that is R/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid, R/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid, S/R-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid, or S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid, or a physiologically acceptable salts salt thereof, for the treatment of treating Parkinson's disease, of treating restless leg syndrome, of treating dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of treating neurological symptoms of chronic manganese intoxications intoxication, of treating amyotrophic lateral sclerosis and of, or treating multiple system atrophy, in addition to and further comprising a pharmaceutically acceptable adjuvants and additives adjuvant or additive.
13. A The pharmaceutical composition, which contains deuterated catecholamines according to of claim 1 as well as physiologically acceptable salts thereof, for the treatment of Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormone, for the treatment of neurological symptoms of chronic manganese intoxications, of amyotrophic lateral sclerosis and of multiple system atrophy, as well as 12, further comprising one or more enzyme inhibitors, in addition to pharmaceutically acceptable adjuvants and additives.
14. The pharmaceutical composition according to of claim 13, further characterized in that wherein the enzyme inhibitor or the enzyme inhibitors involve is a decarboxylase inhibitors inhibitor, and/or a catechol-0O-methyltransferase inhibitors inhibitor, and/or a monoamine oxidase inhibitors inhibitor, and/or a β-hydroxylase inhibitors inhibitor.
15. The pharmaceutical composition according to claim 13 14, further characterized in that wherein the decarboxylase inhibitor is selected from the group consisting of D,L-serine 2-(2,3,4-trihydroxybenzyl) hydrazide (benserazide), (−)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid (carbidopa), L-serine-2-(2,3,4-trihydroxybenzyl) hydrazide, glycine 2-(2,3,4-trihydroxybenzyl) hydrazide and L-tyrosine 2-(2,3,4-trihydroxybenzyl) hydrazide as well as or a physiologically acceptable salts salt thereof.
16. The pharmaceutical composition according to of claim 14, further characterized in that wherein the catechol-0-methyltransferase catechol-O-methyltransferase inhibitor is selected from entacapone and or cabergoline as well as or a physiologically acceptable salts salt thereof.
17. The pharmaceutical composition according to of claim 14, further characterized in that wherein the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and, or tranylcypromine as well as or a physiologically acceptable salts salt thereof.
18. The pharmaceutical composition according to of claim 14, further characterized in that wherein the β-hydroxylase inhibitor is selected from calcium 5-butyl picolinate and or calcium 5-pentyl picolinate as well as or a physiologically acceptable salts salt thereof.
19. The pharmaceutical composition of claim 12, for treating Parkinson's disease.
20. The pharmaceutical composition of claim 12, for treating restless leg syndrome.
21. The pharmaceutical composition of claim 12, for treating dystonia.
22. The pharmaceutical composition of claim 12, for treating chronic manganese intoxication.
23. The pharmaceutical composition of claim 12, for treating amyotrophic lateral sclerosis.
24. The pharmaceutical composition of claim 12, for treating multiple system atrophy.
25. The pharmaceutical composition of any one of claims 19 to 24, wherein the deuterated catecholamine is S/S-2-amino-2,3-dideutero-3-(3,4-dihydroxyphenyl)propionic acid.
US14/464,568 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds Active 2029-07-01 USRE46555E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/464,568 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102006008316 2006-02-17
DE102006008316 2006-02-17
PCT/EP2007/001555 WO2007093450A2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds
US12/224,120 US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds
US14/464,568 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Publications (1)

Publication Number Publication Date
USRE46555E1 true USRE46555E1 (en) 2017-09-19

Family

ID=38236462

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/464,568 Active 2029-07-01 USRE46555E1 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds
US12/224,120 Ceased US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/224,120 Ceased US8247603B2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Country Status (24)

Country Link
US (2) USRE46555E1 (en)
EP (2) EP1991522B1 (en)
JP (1) JP5248331B2 (en)
KR (1) KR101411422B1 (en)
CN (1) CN101384545B (en)
AU (1) AU2007214622B2 (en)
BR (1) BRPI0708071A8 (en)
CA (1) CA2642593C (en)
CY (1) CY1117995T1 (en)
DK (1) DK1991522T3 (en)
EA (1) EA017983B1 (en)
ES (1) ES2587368T3 (en)
HR (1) HRP20161039T1 (en)
HU (1) HUE028777T2 (en)
IL (1) IL193102A (en)
LT (1) LT1991522T (en)
ME (1) ME02508B (en)
PL (1) PL1991522T3 (en)
PT (1) PT1991522T (en)
RS (1) RS55142B1 (en)
SI (1) SI1991522T1 (en)
UA (1) UA97795C2 (en)
WO (1) WO2007093450A2 (en)
ZA (1) ZA200806568B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
NO2303330T3 (en) 2008-06-06 2018-04-14
CA2730734C (en) 2008-07-15 2017-04-25 Theracos, Inc. Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
IN2015DN01662A (en) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
US9567289B2 (en) * 2013-02-05 2017-02-14 Ratiopharm Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
JP6567515B2 (en) * 2013-07-08 2019-08-28 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Dihydroxyphenyl neurotransmitter compounds, compositions and methods
JP2017503756A (en) * 2013-11-22 2017-02-02 オースペックス ファーマシューティカルズ インコーポレイテッド How to treat abnormal muscle activity
EP3424504A1 (en) 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
GB201420341D0 (en) * 2014-11-17 2014-12-31 Evolution Valves Ltd Valve arrangement
MX2017011459A (en) 2015-03-06 2018-04-24 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders.
CN106343013A (en) * 2015-07-19 2017-01-25 中国科学院上海有机化学研究所 Grain storage method
CN105360267B (en) * 2015-10-09 2017-11-10 青岛振坤食品机械有限公司 A kind of automatic skewering machine
AR106313A1 (en) 2015-10-09 2018-01-03 Teva Pharmaceuticals Int Gmbh COMBINATION OF LEVODOPA DEUTERATED WITH CARBIDOPA AND OPICAPONE FOR PARKINSON'S DISEASE TREATMENT
CN105862897B (en) * 2016-04-11 2018-01-16 江苏省华建建设股份有限公司 Sandy Silt ground shallow foundation original groove pouring construction engineering method
BR112021010728A2 (en) * 2018-12-06 2021-08-24 Senda Biosciences, Inc. Decarboxylase Inhibitors for the Treatment of Parkinson's Disease

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
DE2049115A1 (en) 1970-10-06 1972-04-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokio 5-butyl-and5-pentyl-picolinic acids active - as dopamene-b-hydroxylase inhibitors
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
EP0357565A2 (en) 1988-07-12 1990-03-07 Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica New process for the synthesis of the levodopa
US5017607A (en) * 1986-06-10 1991-05-21 Chiesi Farmaceutici S.P.A. Method to treat Parkinsons disease
US5525631A (en) * 1992-12-24 1996-06-11 The Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of the ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10261807A1 (en) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterated catecholamine derivatives and medicinal products containing these compounds
WO2004056306A2 (en) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
DE2049115A1 (en) 1970-10-06 1972-04-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokio 5-butyl-and5-pentyl-picolinic acids active - as dopamene-b-hydroxylase inhibitors
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
US5017607A (en) * 1986-06-10 1991-05-21 Chiesi Farmaceutici S.P.A. Method to treat Parkinsons disease
EP0357565A2 (en) 1988-07-12 1990-03-07 Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica New process for the synthesis of the levodopa
US4962223A (en) 1988-07-12 1990-10-09 Ministero dell'Universita e delle Ricerca Scientifica e Tecnologica Process for the synthesis of the levodopa
US5525631A (en) * 1992-12-24 1996-06-11 The Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of the ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10261807A1 (en) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterated catecholamine derivatives and medicinal products containing these compounds
WO2004056306A2 (en) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
WO2004056724A1 (en) 2002-12-19 2004-07-08 Bdd Berolina Drug Development Gmbh Deuterated catecholamine derivatives and medicaments comprising said compounds
US20060135615A1 (en) * 2002-12-19 2006-06-22 Rudolf-Giesbert Alken Deuterated catecholamine derivatives and medicaments comprising said compounds

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Clinical effect of l-dopa on schizophrenia" Ogura, Chikara; Kishimoto, Akira; Nakao, Takehisa Current Therapeutic Research, vol. 20(3), Sep. 1976, 308-318.
"Comparative metabolism of d- and l-3,4-dihydroxyphenylaline in normal and pyridoxine-deficient rats" T. L Sourkes, Miriam H. Wiseman-Distler, J. F. Moran, G. F. Murphy, and Simonne Saint Cyr Biochem J. Dec. 1964; 93(3): 469-474.
"Deuteriation and tritiation of aryl aldehydes in the formyl group and the synthesis of (±)-3,4-dihydroxy[β-2H2] phenylalanine" D.J. Bennett, G.W. Kirby, and V.A. Moss, J. Chem Soc. C: Organic , 1970, 2049-2051.
"Facile preparation of optically pure [α-2H]-α-amino acids" Shui-Tein Chen, Chen-Chen Tu, and Kung-Tsung Wang Biotechnology Letters vol. 14 No. 4 (Apr. 1992) pp. 269-274.
"Studies on the phenylalanine hydroxylase system in vivo. An in vivo assay based on the liberation of deuterium or tritium into the body water from ring-labeled L-phenylalanine" Sheldon Milstien and Seymour Kaufman J. Biol. Chem. 1975 250: 4782-4785.
"Studies related to the Chemistry of Melanins. Part IX. Synthesis of Specifically Deuterated 3,4-Dihydroxyphenylamines and (+/−)-3,4-Dihydroxyphenylalanines" F. Binns, J. A. G. King, A. Percival, N. C. Robson and G. A. Swan, J. Chem Soc. C: Organic, 1970, 1134-1138.
Claffey et al. Chem. Res. Toxicol. 2001, 14, 1339-1334. *
Dewar et al. Neuro-Psychopharmacology & Biological Psychiatry 1985, 9(5-6), 675-680. *
Dewar et al., "Changes in Brain Catecholamine Levels Following DL-Dopa are not Potentiated by Deuterium Substitution," Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 9:675-80 (1985).
Dyck et al., "Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An In Vivo Study", Journal of Neurochemistry, vol. 46, Issue 2, pp. 399-404, Feb. 1986.
Edwards, et al., Conversion of 3, 4-Dihydroxyphenylalanine and Deuterated 3, 4-Dihydroxyphenylalanine to Alcoholic Metabolites of Catecholamines in Rat Brain, J. Neurochem, May 1981;36(5):1641-7.
Gouyette, A., "Synthesis of Deuterium-Labelled Elliptinium and its Use in Metabolic Studies", Biomedical & Environmental Mass Spectrometry, vol. 15, Issue 5, pp. 243-247, Mar. 1988.
Haskins, Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277, 1982.
Hayashi et al., "Analysis of L-DOPA in vivo Kinetics by the Stable Isotope Tracer Method", Proceedings of Japanese Society for Biomedical Mass Spectrometry, 13, (9) 1988, 229-232.
Kushner, etal., "Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds," Can. J. Physiol. Pharmacol. , 77:79-88 (1999).
Oba et al. "Stereo-divergent Synthesis of L-threo- and L-erythro-[2,3-2H2] amino acids using optically active dioxopiperazine as a chiral template" J. Chem. Soc., Perkin Trans. 1, Jan. 1998.
Stark et al., "Quantitative Analysis of N-Phenylpropenoyl-l-amino Acids in Roasted Coffee and Cocoa Powder by Means of a Stable Isotope Dilution Assay," J. Agric. Food Chem., 2006, 54 (8), pp. 2859-2867.
Tonn et al., "Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10)diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewest†", Biological Mass Spectrometry, vol. 22, Issue 11, pp. 633-642, 1993.
Vining et al., "Deuterium Exchange Labelling of Biologically Important Phenols, Indoles and Steroids", Journal of Labelled Compounds and Radiopharmaceuticals, vol. 18, Issue 11, pp. 1683-1692, Nov. 1981.
Weiner et al. Neurology, 2000, 54(7), p. 1538. *
Wolen, "The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence", The Journal of Clinical Pharmacology, vol. 26, Issue 6, pp. 419-424, Jul.-Aug. 1986.
Yu Biochemistry and Cell biology, 1988, v66(8), 853-861. *
Yu et al., "Stereospecific Deuterium Substitution at the Alpha-Carbon Position of Dopamine and its Effect on Oxidative Deamination Catalyzed by MAO-A and MAO-B from Different Tissues", Biochem Pharmacol. Mar. 15, 1986;35 (6):1027-36.

Also Published As

Publication number Publication date
EP1991522B1 (en) 2016-05-18
EA017983B1 (en) 2013-04-30
SI1991522T1 (en) 2016-10-28
CA2642593C (en) 2014-11-04
ES2587368T3 (en) 2016-10-24
DK1991522T3 (en) 2016-08-29
IL193102A (en) 2015-01-29
CN101384545B (en) 2014-09-03
JP2009526799A (en) 2009-07-23
HRP20161039T1 (en) 2016-11-04
IL193102A0 (en) 2009-02-11
ZA200806568B (en) 2009-07-29
AU2007214622A1 (en) 2007-08-23
EP1991522A2 (en) 2008-11-19
EP3101001A1 (en) 2016-12-07
KR20080106539A (en) 2008-12-08
ME02508B (en) 2017-06-20
CN101384545A (en) 2009-03-11
BRPI0708071A2 (en) 2011-05-17
WO2007093450A2 (en) 2007-08-23
RS55142B1 (en) 2016-12-30
EA200801826A1 (en) 2009-02-27
CY1117995T1 (en) 2017-05-17
AU2007214622B2 (en) 2012-02-23
HUE028777T2 (en) 2017-01-30
EP3101001B1 (en) 2020-04-01
PT1991522T (en) 2016-08-23
UA97795C2 (en) 2012-03-26
BRPI0708071A8 (en) 2017-12-26
CA2642593A1 (en) 2007-08-23
PL1991522T3 (en) 2017-07-31
US8247603B2 (en) 2012-08-21
KR101411422B1 (en) 2014-07-03
JP5248331B2 (en) 2013-07-31
US20090018191A1 (en) 2009-01-15
WO2007093450A3 (en) 2007-09-27
LT1991522T (en) 2016-09-26

Similar Documents

Publication Publication Date Title
USRE46555E1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
US7462737B2 (en) Pregabalin free of isobutylglutaric acid and a process for preparation thereof
EP0610595A2 (en) Composition of l-dopa esters
JP2018193356A (en) Deuterated catecholamine derivatives and medicaments comprising those compounds
US20220000814A1 (en) Methods for treatment of prader-willi syndrome

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMPHAR AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES;REEL/FRAME:035255/0900

Effective date: 20150130

AS Assignment

Owner name: RATIOPHARM GMBH, GERMANY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:IMPHAR AKTIENGESELLSCHAFT;RATIOPHARM GMBH;REEL/FRAME:039552/0001

Effective date: 20160614

AS Assignment

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, SWITZERLA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RATIOPHARM GMBH;REEL/FRAME:041420/0200

Effective date: 20170222

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY